C57BL/6NCya-Hsd17b13em1/Cya
Common Name:
Hsd17b13-KO
Product ID:
S-KO-07421
Background:
C57BL/6NCya
Product Type
Age
Genotype
Sex
Quantity
Price:
Contact for Pricing
Basic Information
Strain Name
Hsd17b13-KO
Strain ID
KOCMP-243168-Hsd17b13-B6N-VA
Gene Name
Product ID
S-KO-07421
Gene Alias
PAN1B-like; Pan1b
Background
C57BL/6NCya
NCBI ID
Modification
Conventional knockout
Chromosome
5
Phenotype
Document
Application
--
Note: When using this mouse strain in a publication, please cite “C57BL/6NCya-Hsd17b13em1/Cya mice (Catalog S-KO-07421) were purchased from Cyagen.”
Strain Description
Ensembl Number
ENSMUST00000048118
NCBI RefSeq
NM_198030
Target Region
Exon 2~6
Size of Effective Region
~6.9 kb
Detailed Document
Overview of Gene Research
HSD17B13, hydroxysteroid 17-β dehydrogenase family 13, is a liver-specific, lipid droplet-associated protein [3,5,8]. It has enzymatic pathways involving steroids, pro-inflammatory lipid mediators and retinol [8]. The 17β-Hydroxysteroid dehydrogenases (HSD17Bs) family, to which HSD17B13 belongs, is mainly involved in sex hormone metabolism, and some members also play roles in cholesterol and fatty acid metabolism [3]. Genetic models, such as gene knockout in mice, are valuable for studying its functions.
In mice, knockdown of Hsd17b13 protects against liver fibrosis in non-alcoholic steatohepatitis, associated with decreased pyrimidine catabolism at the level of dihydropyrimidine dehydrogenase [2]. Also, hepatic overexpression of HSD17B13 in mice promotes lipid accumulation in the liver [3]. The rs72613567-TA variant in HSD17B13, which leads to a loss-of-function, is associated with reduced risk of chronic liver diseases in humans and mitigates liver injury in mouse models [4]. Adeno-associated viral-mediated xeno-expression of human HSD17B13 exacerbates western diet/carbon tetrachloride-induced liver inflammation in Hsd17b13-/-mice [7].
In conclusion, HSD17B13 plays a role in hepatic lipid homeostasis and liver inflammation. Loss-of-function models, including gene knockout in mice, have revealed its contribution to the development of non-alcoholic fatty liver disease (NAFLD), liver fibrosis, and chronic liver inflammation. These findings suggest HSD17B13 could be a potential therapeutic target for treating related liver diseases [1,2,3,4,5,6,7,8,9].
References:
1. Zhang, Hai-Bo, Su, Wen, Xu, Hu, Zhang, Xiao-Yan, Guan, You-Fei. 2022. HSD17B13: A Potential Therapeutic Target for NAFLD. In Frontiers in molecular biosciences, 8, 824776. doi:10.3389/fmolb.2021.824776. https://pubmed.ncbi.nlm.nih.gov/35071330/
2. Luukkonen, Panu K, Sakuma, Ikki, Gaspar, Rafael C, Petersen, Kitt Falk, Shulman, Gerald I. 2023. Inhibition of HSD17B13 protects against liver fibrosis by inhibition of pyrimidine catabolism in nonalcoholic steatohepatitis. In Proceedings of the National Academy of Sciences of the United States of America, 120, e2217543120. doi:10.1073/pnas.2217543120. https://pubmed.ncbi.nlm.nih.gov/36669104/
3. Su, Wen, Mao, Zhuo, Liu, Yiao, Gustafsson, Jan-Ake, Guan, Youfei. 2018. Role of HSD17B13 in the liver physiology and pathophysiology. In Molecular and cellular endocrinology, 489, 119-125. doi:10.1016/j.mce.2018.10.014. https://pubmed.ncbi.nlm.nih.gov/30365983/
4. Abul-Husn, Noura S, Cheng, Xiping, Li, Alexander H, Gromada, Jesper, Dewey, Frederick E. . A Protein-Truncating HSD17B13 Variant and Protection from Chronic Liver Disease. In The New England journal of medicine, 378, 1096-1106. doi:10.1056/NEJMoa1712191. https://pubmed.ncbi.nlm.nih.gov/29562163/
5. Motomura, Takashi, Amirneni, Sriram, Diaz-Aragon, Ricardo, Florentino, Rodrigo M, Soto-Gutierrez, Alejandro. 2021. Is HSD17B13 Genetic Variant a Protector for Liver Dysfunction? Future Perspective as a Potential Therapeutic Target. In Journal of personalized medicine, 11, . doi:10.3390/jpm11070619. https://pubmed.ncbi.nlm.nih.gov/34208839/
6. Wang, P, Wu, C-X, Li, Y, Shen, N. . HSD17B13 rs72613567 protects against liver diseases and histological progression of nonalcoholic fatty liver disease: a systematic review and meta-analysis. In European review for medical and pharmacological sciences, 24, 8997-9007. doi:10.26355/eurrev_202009_22842. https://pubmed.ncbi.nlm.nih.gov/32964989/
7. Ye, Jing, Huang, Xiyu, Yuan, Manman, Xu, Qiang, Wu, Xingxin. . HSD17B13 liquid-liquid phase separation promotes leukocyte adhesion in chronic liver inflammation. In Journal of molecular cell biology, 16, . doi:10.1093/jmcb/mjae018. https://pubmed.ncbi.nlm.nih.gov/38692847/
8. Amangurbanova, Maral, Huang, Daniel Q, Loomba, Rohit. 2022. Review article: the role of HSD17B13 on global epidemiology, natural history, pathogenesis and treatment of NAFLD. In Alimentary pharmacology & therapeutics, 57, 37-51. doi:10.1111/apt.17292. https://pubmed.ncbi.nlm.nih.gov/36349732/
9. Stender, Stefan, Romeo, Stefano. . HSD17B13 as a promising therapeutic target against chronic liver disease. In Liver international : official journal of the International Association for the Study of the Liver, 40, 756-757. doi:10.1111/liv.14411. https://pubmed.ncbi.nlm.nih.gov/32255570/
Quality Control Standard
Sperm Test
Pre-cryopreservation: Measurement of sperm concentration, determination of sperm viability.
Post-cryopreservation: A vial of cryopreserved sperms is selected for in-vitro fertilization from each batch.
Environmental Standards:SPF
Available Region:Global
Source:Cyagen